Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW679769 morning dosing crossover study in primary insomnia
2005-004889-17Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vercirnon in Insomnia (3 arms), sponsored by GSK. Primary endpoint: Latency to persistent sleep. Started Mar 2006; status: completed.
02
Drugs
vercirnon
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2005-004889-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004889-17.